CN106955270A - A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application - Google Patents
A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application Download PDFInfo
- Publication number
- CN106955270A CN106955270A CN201710247338.0A CN201710247338A CN106955270A CN 106955270 A CN106955270 A CN 106955270A CN 201710247338 A CN201710247338 A CN 201710247338A CN 106955270 A CN106955270 A CN 106955270A
- Authority
- CN
- China
- Prior art keywords
- ambroxol hydrochloride
- medicine
- oral solution
- treatment
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to chemicals technical field, entitled a kind of ambroxol hydrochloride oral solution and preparation method thereof and new application, its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, citric acid 0.22g is added, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, and mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution；Application of the ambroxol hydrochloride medicine in treatment diabetes, diabetes mellitus encephalopathy, diabetic nephropathy is prepared.The present invention provides the technique extension clinical application of ambroxol hydrochloride, at the same be also diabetes, the treatment of the disease such as diabetes mellitus encephalopathy, diabetic nephropathy provide new medication selection and clinic diagnosis scheme.
Description
Technical field：
The present invention relates to chemicals technical field, more particularly to a kind of ambroxol hydrochloride medicine and its new pharmaceutical use.
Technical background：
Ambroxol hydrochloride, chemical name is：Trans -4- [(2- amino -3,5- dibromo-benzyl) amino] cyclohexanol HCI,
Molecular formula is C13H18Br2N2OHCL, structural formula is as follows：
Ambroxol hydrochloride is white to slightly yellow crystalline powder；Almost odorless.Sticky secretion inside respiratory tract can be promoted
The exclusion of thing and the delay for reducing mucus, thus remarkably promote expectoration.Suitable for secreting abnormal and expectoration function with sputum
Bad acute, chronic respiratory disease.
Ambroxol hydrochloride is expectorant, has good glutinous phlegm dissolution and lubrication respiratory tract effect, can promote lung surface
The secretion of active material, the secretion and ciliary movement for breathing liquid etc..It is abnormal etc. for acute and chronic breathing problem, bronchial secretion
Treatment.Ambroxol hydrochloride can be additionally used in treatment Bronchopneumonia, chronic obstructive pulmonary disease, bronchiolitis, secretory
The diseases such as otitis, chronic bronchitis.
Inventor chances in clinic diagnosis practice, to Diabetic Nephropathy patients, especially diabetic nephropathy kidney
Loose patient gives ambroxol hydrochloride therapy, achieves highly significant curative effect.
After specification, science, rigorous clinical test and pharmacodynamic experiment is carried out, technical scheme has been obtained.
The content of the invention：
It is an object of the invention to provide a kind of ambroxol hydrochloride medicine and preparation method thereof.
Treatment diabetes, diabetes mellitus encephalopathy, glycosuria are being prepared it is a further object of the present invention to provide ambroxol hydrochloride medicine
Application in sick nephrosis, myocarditis, vital myocarditis medicine.
The purpose of the present invention is achieved in the following ways：
A kind of ambroxol hydrochloride medicine, the medicine is ambroxol hydrochloride oral solution, and its preparation method is：Take hydrochloric acid ammonia bromine
Rope 3g, adds Sucralose 0.4g, Steviosin 0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol
7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, and mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride mouthful
Take solution.
A kind of application of ambroxol hydrochloride medicine in treatment diabetes medicament is prepared, the ambroxol hydrochloride medicine is hydrochloric acid
Ambroxol oral liquid, its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, citric acid is added
0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, mix
Even, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
A kind of application of ambroxol hydrochloride medicine in treatment diabetes mellitus encephalopathy medicine is prepared, the ambroxol hydrochloride medicine is
Ambroxol hydrochloride oral solution, its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, Chinese holly is added
Rafter acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water are added to
1000mL, mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
A kind of application of ambroxol hydrochloride medicine in treatment medicine for treating diabetic nephropathy is prepared, the ambroxol hydrochloride medicine is
Ambroxol hydrochloride oral solution, its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, Chinese holly is added
Rafter acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water are added to
1000mL, mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
Application of the described ambroxol hydrochloride in treatment diabetic nephropathy renal hypertrophy medicine is prepared.
A kind of application of ambroxol hydrochloride medicine in treatment myocarditis medicine is prepared, the ambroxol hydrochloride medicine is hydrochloric acid
Ambroxol oral liquid, its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, citric acid is added
0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, mix
Even, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
Application of the described ambroxol hydrochloride medicine in treatment vital myocarditis medicine is prepared.
Brief description of the drawings：
Fig. 1 cuts into slices for normal rat Pathological
Fig. 2 is 12 weeks pathological sections of Diabetic nephropathy animal model group
Fig. 3 is 12 weeks pathological sections of diabetic nephropathy rats treatment group
Embodiment：
Embodiment 1：The pharmacodynamic experiment research of ambroxol hydrochloride therapy diabetic nephropathy rats
1 materials and methods
1.1 reagents and instrument
Streptozotocin (STZ) is produced by Beijing Suo Laibao Science and Technology Ltd；Urine detection tetrad reagent strip, by Anhui
Dark blue medical science and technology limited company production；Coomassie brilliant blue reagent (CBB), is given birth to by Beijing Suo Laibao Science and Technology Ltd
Production；Metal metabolism cage, is produced by Suzhou Feng Shi experimental animal equipment Co., Ltd；755 type ultraviolet-uisible spectrophotometers, by upper
Hai Aoxi scientific instrument Co., Ltd produces；Blood glucose meter, is produced by Beijing is happy into biological electronic technology limited company.Hydrochloric acid
Ambroxol oral liquid：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, citric acid 0.22g, citric acid is added
Sodium 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, mix, filtering, it is filling,
Sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution, are produced by Heilungkiang Zhong Gui pharmaceutical Co. Ltds, specification 5mL:15mg.
1.2 experimental animals
Bull Wislar rats 30, SPF grades, 200 ± 20g of body weight, purchased from Heilongjiang University of Chinese Medicine animal
The heart is provided.Animal quality certification number：The dynamic word the 1024-03rd of doctor.Experimental animal is raised precedently 24 hours in advance, adapts to laboratory and raises
The condition of supporting.All animals watch material with high pressure and fed, and arbitrarily drinking-water, ingests, and room temperature is controlled in 25 DEG C or so, natural lighting.
1.3 animal models make and packet
30 rats are randomly divided into 3 groups, normal group, model treatment group and model non-treatment group, every group 10.Model group
Fasting 12h (can't help water) before rat experiment.Streptozotocin is dissolved in the citrate buffers of pH 4.2, by 50mg/Kg once
Property intraperitoneal injection, the blood sugar concentration that animal after glucose in urine, 3d is monitored daily is more than 16.7mmoL/L, and glucose in urine is positive, is defined as sugar
Urine disease model is formed.Ambroxol hydrochloride oral solution 0.5mg/Kg gives in treatment group, gavage, and 2 times a day, treats 4 weeks altogether.Glycosuria
Disease substantially increases into Urine proteins after mould 3 weeks, and diabetic nephropathy model is set up.During testing rat show as many drinks, many foods,
Diuresis, the symptom such as become thin.Normal group gives isometric citrate buffer.
1.4 collections of specimens and detection
Rat is put into clean metal metabolism cage, each group rat 24h Urine specimens is collected before and after treatment, during staying urine
Fasting, can't help taking 4mL after water, record urine volume, 2000r/min centrifugation 10min remove sediment and treated in -20 DEG C of Refrigerator stores
Survey.Urine proteins are detected with Coomassie Brilliant Blue.After experiment terminates, rat is anesthetized with ether, eyeball is plucked and takes blood, for blood glucose, blood
The detection of creatinine, urea nitrogen.Blood glucose blood glucose meter and blood sugar test paper detection, renal function are detected using Beckman automatic biochemical analyzers.
1.5 Renal Paphologies are detected
Anesthetized rat is taken after blood, and kidney is taken out immediately, is removed coating, is weighed, 10% formalin is fixed, and alcohol takes off step by step
Water, dimethylbenzene is transparent, FFPE.Slice thickDo conventional H E dyeing to dye with PAS, om observation.
1.6 statistical methods
Using SPSS10.0 software data processings, all data are with average value standard deviationRepresent, compare between group and use t
Examine.
2 results
2.1 changes of each group rat urine protein content afterwards before the treatment
After diabetes model is set up 4 weeks, the increase of rat Urine proteins, after being treated through ambroxol hydrochloride oral solution, Urine proteins
Reduce, compared with pre-treatment compared with difference significance (P<0.05).And non-treatment group's Urine proteins have the trend increased, but it is poor
Different nonsignificance (P>0.05), it is shown in Table 1.
The change of Urine proteins before and after the treatment of each group rat of table 1
Note：Compared with before treatment, * P<0.05；Compared with before treatment, #P>0.05.
The change of each group rat blood serum, blood biochemistry index and kidney weight/body weight after 2.2 treatments
Model group blood glucose is apparently higher than normal group (P<, but serum creatinine, urea nitrogen difference are without clear meaning (P 0.01)>
0.05), treatment group is given after ambroxol hydrochloride oral solution treatment, and kidney weight/body mass index is significantly lower than non-treatment group (P<
0.05), with normal group difference without clear meaning (P>0.05), illustrate that ambroxol hydrochloride oral solution can mitigate diabetic nephropathy
The renal hypertrophy of rat, is shown in Table 2.
Blood glucose, blood urea nitrogen, creatinine and kidney weight/changes of weight after the treatment of table 2
Compared with normal group, * P<0.05, * * P<0.01.
Influence of 2.3 ambroxol hydrochloride oral solutions to diabetic nephropathy tectology
HE dyeing can see normal rats extracellular matrix under light microscopic and mesangial cell distribution is normal, capillary lumen
It is open, see that accompanying drawing 1, rather than the extracellular matrix for the treatment of group increase, system cells hyperplasia, while capillary vessel member is collapsed, is shown in
Accompanying drawing 2.Treatment group's extracellular matrix slightly increases, and proliferation of mesangial cells also mitigates.Glomerular basement membrane thickening mitigates, and sees accompanying drawing
3, illustrate that ambroxol hydrochloride oral solution can mitigate glomerulus hypertrophy to a certain extent, so as to have necessarily to diabetic nephropathy
Therapeutic action.
3 conclusions
This experiment shows that ambroxol hydrochloride oral solution can reduce the urinary protein excretion of diabetic nephropathy rats, reduction
Kidney weight/body mass index, pathological data confirms that model treatment group extracellular matrix build-up is reduced, and mesentery expansion and mesangial cell increase
It is raw to mitigate, illustrate that ambroxol hydrochloride oral solution has certain effect to treatment diabetic nephropathy renal hypertrophy.
Embodiment 2：Ambroxol hydrochloride oral solution is studied the pharmacodynamic experiment of diabetes mellitus encephalopathy rat
Diabetes are one group of lifelong participation metabolic diseases being characterized as caused by multi-pathogenesis with chronic hyperglycemia.Long-term blood
Sugar increases, and big blood vessel, capilary are damaged and jeopardize the heart, brain, kidney, peripheral nerve, eyes, foot etc., are counted according to the World Health Organization,
Diabetic complication is up to kind more than 100, is to be currently known a kind of most disease of complication, common are diabetic nephropathy, sugar
Urinate characteristic of disease PVR, the uveitis related to diabetes, diabetic cataract, diabetes, diabetes mellitus encephalopathy, sugar
The sick cardiovascular complication of urine, diabetic cerebrovascular disease, diabetic neuropathy etc..Diabetes Death person has more than half to be
Caused by cardiovascular and cerebrovascular, caused by 10% is nephropathy.Because the patient of diabetes amputation is 10~20 times of non-diabetic.Clinical data
10 years or so after display, onset diabetes, there will be 30%~40% patient that a kind of complication, and complication one occur to I haven't seen you for ages
Denier is produced, and drug therapy is difficult to reverse, therefore emphasizes to prevent diabetic complication as early as possible.Ambroxol hydrochloride oral solution can be controlled
Treat diabetic nephropathy, then predict that it also has certain therapeutic effect to diabetes mellitus encephalopathy.Inventor is to ambroxol hydrochloride mouthful
Take Solution In The Treatment diabetes mellitus encephalopathy and carry out pharmacodynamic experiment research, probe into its therapeutic effect.
1 material and method
1.1 experimental animals and reagent
The male 8 week old SD rats of health, 200~250g of weight is provided purchased from Heilongjiang University of Chinese Medicine's animal center.
Animal quality certification number：The dynamic word the 1024-03rd of doctor.Watermaze protocol auto-controller, by the limited public affairs of Hefei four seas instrument science and technology
Department's production；Streptozotocin (STZ), is produced by Beijing Suo Laibao Science and Technology Ltd；Ambroxol hydrochloride oral solution：Take hydrochloric acid
Ambroxol 3g, adds Sucralose 0.4g, Steviosin 0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol 0.1g, second
Alcohol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, and mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride
Oral administration solution, is produced, specification 5mL by Heilungkiang Zhong Gui pharmaceutical Co. Ltds:15mg.
The foundation and packet of 1.2 diabetes rat models
Rat adaptability is raised 1 week, fasting 12h, is diluted by 4.5 0.1moL/L sodium citrate buffers of pH after STZ,
Lucifuge simultaneously quickly sets up diabetes rat model with the injection of 60mg/Kg amounts disposable celiac.After 3d, modeling Rat Septal curfew eats not
Prohibit drink more than 8h, take rat tail vein blood examination to survey fasting blood sugar, by fasting blood-glucose>It is big that 18mmoL/L rat is set to diabetes
Mouse, rejects the below standard person of blood glucose.Model successfully after one week, diabetes rat is randomly divided into diabetes mellitus encephalopathy group and hydrochloric acid ammonia bromine
Rope oral administration solution treatment group, every group 10；Normal rat is randomly divided into Normal group and ambroxol hydrochloride oral solution control
Group, every group 10.Ambroxol hydrochloride mouthful is given by ambroxol hydrochloride oral solution treatment group, ambroxol hydrochloride oral solution control group
Solution 10mg/ (Kgd) gavage is taken, Normal group gives Isodose physiological saline gavage, continues 14 weeks.In experimentation
In, each group rat weight and blood glucose value are detected weekly.
1.3 Morris water maze laboratories
At the 14th week, using the observation Cognition Function in Rats change of Morris water mazes.Morris water mazes are a diameter
200cm round pool, is built-in with the circular platform (diameter 15cm) of a moveable position, and platform is located at 2cm under water, and water temperature is permanent
It is scheduled on (25 ± 2) DEG C.Water maze laboratory has 6d altogether, is within the 1st day the water maze environment laundering period.It is within 2nd~5 day the Experiment Training phase,
Record is from being put into a little to the time used by platform i.e. escape latency, and each testing time is 120s, will be big if not finding platform
Mouse leads to platform and makes it stop 10~15s to remember gate position.It is within 6th day space search experiment, withdraws platform, surveys every time
The examination time is 60s, records every rat in the platform traversing times of platform position and hovering the time in purpose quadrant.
1.4 heart perfusions and collection of specimens
After water maze laboratory terminates, 1 rat is randomly selected from every group, 3mL/Kg abdominal cavities of being waken up with 10% hydration chlorine are injected into
Row anesthesia, fixes and cuts off after thoracic cavity exposure heart, separation pericardium, catheter needle insertion left ventricle and fixation, while cutting off the right side
Atrium.First got express developed, then slowly irrigated with 4% paraformaldehyde with physiological saline.After fully being fixed in rat body, cut
Skull is opened, whole brain, which is completely moved in 4% paraformaldehyde, to soak 3d and wait embedding is used for H-E dyeing.Remaining rat is broken
Head takes brain, is placed in quick separating on ice and goes out hippocampus, is put into cryopreservation tube and is stored in -120C for western blot analysis.
1.5 H-E are dyed
Row serial section after the tissue of FFPE is fixed with Coronal, by the section containing hippocampal tissue paste through
It is placed in 60~65 DEG C of baking boxs baking 30~60min of piece on the treated slide of 3- aminopropyl -3- methoxy silanes (APES).
Section dewaxing to water, hematoxylin solution is contaminated, and rinses unnecessary dye liquor, is then dehydrated with graded ethanol, last mounting.Optical microphotograph
Microscopic observation Rat hippocampus CA1 area's neuron morphologies and its pathological change.
1.6 statistical procedures
All numerical value using SPSS10.0 softwares carry out statistical analysis, data with (Form represents, with multifactor and
One-way analysis of variance compares group difference.Inspection level (a) is 0.05.
2 results
The ordinary circumstance of 2.1 each group rats
There is obvious many drink, diuresis, polyphagia shapes in diabetes rat, and rat hair color sallow is One's spirits are drooping, and rat-tail occurs
Different degrees of festers and the phenomenon that docks.When testing 2 months, diabetes rat is suffered from diarrhoea and subcutaneous abscess because of infection appearance, is passed through
After the injection treatment of antibiotic abdominal cavity, infection symptoms are controlled.Diabetes rat is slow in action, and autonomous actions are reduced, and is occurred easy
The behavior expression such as excitation or to external world stimulate the reaction be indifferent.During experiment, blood glucose in diabetic rats value is maintained at (27 ± 6)
MmoL/L, while normal rat blood glucose value is maintained at (6 ± 2) mmoL/L.
2.2 water maze laboratory results
After rat blood sugar value is persistently raised 3 months, during water maze laboratory is trained, diabetes mellitus encephalopathy group and hydrochloric acid ammonia
Xiu Suo oral administration solutions treatment group escape latency substantially increases (P compared with Normal group<0.01), experimental result is shown in Table 3.
Water maze is formally during experiment, and diabetes mellitus encephalopathy group and ambroxol hydrochloride oral solution treat group platform traversing times
(P is significantly reduced with the time of hovering in purpose quadrant compared with Normal group<0.01), experimental result is shown in Table 4.
The each group rat water maze of table 3 tests the comparison of escape latency
Note：Compared with normal control, * * P<0.01；
The each group rat water maze space search experiment porch traversing times of table 4 and purpose quadrant are hovered time n=6,
Note：Compared with normal control, * * P<0.01；
3 conclusions
This experimental studies have found that, ambroxol hydrochloride oral solution successive administration after 14 weeks observe ambroxol hydrochloride oral it is molten
Liquid treatment group Cognition Function in Rats obstacle without be improved significantly, show ambroxol hydrochloride oral solution to diabetes rat all
Brain does not have significant protective effect, it is impossible to effectively treat diabetes mellitus encephalopathy.
Claims (7)
1. a kind of ambroxol hydrochloride medicine, the medicine is ambroxol hydrochloride oral solution, it is characterised in that its preparation method is：
Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin 0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol is added
0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add to 1000mL, and mixing, filtering, filling, sterilizing, lamp inspection obtain salt
Sour ambroxol oral liquid.
2. a kind of application of ambroxol hydrochloride medicine in treatment diabetes medicament is prepared, it is characterised in that the ambroxol hydrochloride
Medicine is ambroxol hydrochloride oral solution, and its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin is added
0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add
To 1000mL, mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
3. a kind of application of ambroxol hydrochloride medicine in treatment diabetes mellitus encephalopathy medicine is prepared, it is characterised in that the hydrochloric acid ammonia
Bromine rope medicine is ambroxol hydrochloride oral solution, and its preparation method is：Take ambroxol hydrochloride 3g, add Sucralose 0.4g, it is sweet
Chrysanthemum element 0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purifying
Water adds to 1000mL, and mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
4. a kind of application of ambroxol hydrochloride medicine in treatment medicine for treating diabetic nephropathy is prepared, it is characterised in that the hydrochloric acid ammonia
Bromine rope medicine is ambroxol hydrochloride oral solution, and its preparation method is：Take ambroxol hydrochloride 3g, add Sucralose 0.4g, it is sweet
Chrysanthemum element 0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purifying
Water adds to 1000mL, and mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
5. application of the ambroxol hydrochloride medicine according to claim 4 in treatment medicine for treating diabetic nephropathy is prepared, it is special
Levy and be, application of the medicine in treatment diabetic nephropathy renal hypertrophy medicine is prepared.
6. a kind of application of ambroxol hydrochloride medicine in treatment myocarditis medicine is prepared, it is characterised in that the ambroxol hydrochloride
Medicine is ambroxol hydrochloride oral solution, and its preparation method is：Ambroxol hydrochloride 3g is taken, Sucralose 0.4g, Steviosin is added
0.7g, citric acid 0.22g, sodium citrate 0.16g, menthol 0.1g, ethanol 7.5mL, flavoring pineapple essence 0.1mL, plus purified water add
To 1000mL, mixing, filtering, filling, sterilizing, lamp inspection obtain ambroxol hydrochloride oral solution.
7. application of the ambroxol hydrochloride medicine according to claim 6 in treatment myocarditis medicine is prepared, its feature exists
In application of the medicine in treatment vital myocarditis medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710247338.0A CN106955270B (en) | 2017-04-14 | 2017-04-14 | A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710247338.0A CN106955270B (en) | 2017-04-14 | 2017-04-14 | A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106955270A true CN106955270A (en) | 2017-07-18 |
| CN106955270B CN106955270B (en) | 2018-04-27 |
Family
ID=59483559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710247338.0A Active CN106955270B (en) | 2017-04-14 | 2017-04-14 | A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106955270B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1531429A (en) * | 2001-05-28 | 2004-09-22 | ����ķ�ֿ˱������ɷݹ�˾ | Medicament, containing effector of glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| CN101103968A (en) * | 2006-07-14 | 2008-01-16 | 海南盛科生命科学研究院 | Ambroxol oral liquid with good taste |
| CN102225049A (en) * | 2011-06-17 | 2011-10-26 | 成都金典药物科技开发有限公司 | Preparation method of ambroxol hydrochloride injection with stable pH value |
| CN106491703A (en) * | 2016-12-21 | 2017-03-15 | 郑州莉迪亚医药科技有限公司 | A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application |
-
2017
- 2017-04-14 CN CN201710247338.0A patent/CN106955270B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1531429A (en) * | 2001-05-28 | 2004-09-22 | ����ķ�ֿ˱������ɷݹ�˾ | Medicament, containing effector of glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| CN101103968A (en) * | 2006-07-14 | 2008-01-16 | 海南盛科生命科学研究院 | Ambroxol oral liquid with good taste |
| CN102225049A (en) * | 2011-06-17 | 2011-10-26 | 成都金典药物科技开发有限公司 | Preparation method of ambroxol hydrochloride injection with stable pH value |
| CN106491703A (en) * | 2016-12-21 | 2017-03-15 | 郑州莉迪亚医药科技有限公司 | A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106955270B (en) | 2018-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432572B (en) | A kind of preparation method of rhesus monkey diabetic nephropathy model | |
| CN109221011A (en) | A method of the SD Obesity of Rats and diabetes study model established by diet and STZ induction | |
| CN106857406A (en) | A kind of method for building up by diet induced SD rat diabetes animal models | |
| US20150284687A1 (en) | Cell therapy: a method and a composition for treating diabetes | |
| Mota et al. | The analysis of prevalence and incidence of diabetes mellitus in Romania | |
| CN109045282A (en) | A method of delaying premature ovarian failure and treatment osteoporosis using navel blood stem cell infusion joint autologous peripheral blood stem cells | |
| CN102114170B (en) | Traditional Chinese medicine composition for preventing and treating myocardial ischemia reperfusion injury and preparation method thereof | |
| CN106955270B (en) | A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application | |
| CN104146990A (en) | Application of phloretin in preparation of medicine for preventing and/or treating diabetes | |
| CN104096218B (en) | Application of recombinant human cytoglobin in preparation of drugs treating hyperlipidemia and atherosclerosis | |
| CN110522758A (en) | Aucubin is preparing the purposes in the drug for treating diabetes B | |
| CN105596458A (en) | Jinqi glucose-lowering tablet for treating diabetic cardiovascular complications | |
| CN105596684A (en) | Rhizoma anemarrhenae extract and lily and rhizoma anemarrhenae extract | |
| CN106860449A (en) | Purposes of the matrine derivative in diabetes are treated | |
| CN105250248A (en) | Application of astaxanthin in preparation of drugs for prevention and treatment of glomerular fibrosis and edema | |
| CN111481535B (en) | Application of IDHP in preparation of anti-septicemia and myocardial damage drug induced by IDHP | |
| CN107875144A (en) | A kind of combination of oral medication for treating depression | |
| KR100542809B1 (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
| CN107334775A (en) | THPA is preparing the application in treating atherosclerosis medicine | |
| CN113577102A (en) | Application of iron nanocluster in preparation of anti-septicemia and myocardial damage drug induced by same | |
| WO2011116501A1 (en) | Establishment of rhesus monkey model of autoimmunity type 1 diabetes | |
| Magyar et al. | Sugar consumption in vitro of the muscle tissue of diabetic patients | |
| CN111956643B (en) | Application of verteporfin in preparing obesity medicine | |
| CN105251018B (en) | NONRATT021972 siRNA is applied in preparation its dysfunction of nerve fiber and related disease drug | |
| WO2021114255A1 (en) | Method for studying brain-intestine neural circuit and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gong Yujing Inventor after: Wang Cheng Inventor after: Yu Jia Inventor after: Tian Yongjie Inventor after: Wei Guodong Inventor after: Wang Chunling Inventor after: Ge Lili Inventor after: Ren Yali Inventor after: Liu Haisheng Inventor after: Lv Kai Inventor after: Guo Jinfeng Inventor after: Han Miao Inventor after: Gu Jingxue Inventor after: Liu Jia Inventor after: Yin Lili Inventor before: Zhang Shucheng Inventor before: Gong Yujing Inventor before: Zhang Qing Inventor before: Liu Zhiru Inventor before: Han Miao Inventor before: Wang Wenxin Inventor before: Zhang Guofeng |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |